Old weapon, new target: Dasatinib against angioimmunoblastic T-cell lymphoma

Old weapon, new target: Dasatinib against angioimmunoblastic T-cell lymphoma: (University of Tsukuba) Researchers from the University of Tsukuba have shown by in vivo experimentation on a mouse model that angioimmunoblastic T-cell lymphoma is highly dependent on T-Cell Receptor Signaling. Further trials also suggest that dasatinib, by targeting the TCR pathway, improved outcomes in both the mouse model and in a clinical trial of five patients who relapsed or were refractory to conventional therapy and therefore showed promise as a candidate drug for AITL treatment.